ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0555

Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0493

Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0570

Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0466

Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0318

Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study

(0306–0336) Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0276

Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0130

Plasminogen activator inhibitor 1 increases thrombotic risk in Antiphospholipid syndrome

(0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0624

Polygenic risk of lupus is differentially associated with individual EHR-derived classification criteria

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0145

Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina

(0145–0174) Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0225

Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses

(0210–0232) Measures & Measurement of Healthcare Quality Poster I

10:30AM-12:30PM: Abstract Number: 0151

Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023

(0145–0174) Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0601

Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0262

Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0414

Predicting JIA-Associated Uveitis Using Tear Fluid Biomarkers: A Prospective Multicenter Study

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0111

Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures

(0098–0114) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].